RESUMO
ABSTRACT: Breast mass is a common finding in patients presenting to primary care, women's health, or urgent care clinics. There are multiple etiologies that can cause a palpable breast mass both benign and malignant. PAs must know how to approach a patient with a palpable breast mass as well as what appropriate diagnostic evaluation is needed.
Assuntos
Neoplasias da Mama , Mama , Mama/diagnóstico por imagem , Mama/patologia , Neoplasias da Mama/diagnóstico por imagem , Neoplasias da Mama/patologia , Feminino , HumanosRESUMO
BackgroundFatigue in myasthenia gravis (MG) is common and difficult to manage. Unlike myasthenic weakness it is not amenable to drug therapies.ObjectiveOur primary aim was to investigate whether a combination of physical and psychological therapy would help address symptoms of fatigue in MG patients, who have stable disease but residual problematic fatigue. Our secondary aim was to quantitate fatigue by applying different scores and to ascertain which would be most relevant to apply in MG.MethodsWe recruited 10 MG patients with stable disease and who suffer from fatigue. Nine of these 10 patients participated in a 10-week program that involved physical and psychological intervention. We quantified their fatigue using the modified fatigue impact scale (MFIS), the visual analogue fatigue scale (VAFS) and the fatigue severity scale (FSS) at the start of the study, at various intervals during the program and 3 months later.ResultsDuring the program, there was a small improvement in the physical and psychosocial subscale of the MFIS. There was a significant improvement (p < 0.01) in the VAFS at the end of the program. No clear improvement was noted in FSS. Three months later, all fatigue scores declined to baseline but 50% of patients had made some life-style changes.ConclusionsThis is a small pilot study, which utilized a combined approach with physical and psychological therapy, and showed some benefit in improving fatigue in patients with MG. The improvement was small and unsustained. Because of the small patient cohort, one cannot derive any firm conclusions and a larger study is required to investigate this further.
Assuntos
Fadiga/psicologia , Fadiga/terapia , Miastenia Gravis/psicologia , Miastenia Gravis/terapia , Adulto , Idoso , Terapia Combinada , Fadiga/etiologia , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Debilidade Muscular/etiologia , Debilidade Muscular/terapia , Miastenia Gravis/complicações , Equipe de Assistência ao Paciente , Modalidades de Fisioterapia , Projetos Piloto , Psicoterapia , Resultado do TratamentoRESUMO
Ocular myasthenia is the milder end of the myasthenia gravis spectrum but treatment can be challenging especially in older patients. We retrospectively studied all patients on our database with ocular myasthenia (OMG), positive for acetylcholine receptor (AChR) antibodies. We identified 93 patients (64 men and 29 women). The mean age at disease onset was 63y, median 68y. Most (72%) experienced ptosis with diplopia; 19% experienced ptosis alone, while 7.5% complained of diplopia without ptosis. As expected, pyridostigmine was commenced early at diagnosis in the majority (69%) and 20% were still receiving pyridostigmine at final review. Immunosuppression was prescribed in 50%. Seven patients had ptosis repair surgery; 20 patients used prisms at some stage. >75% had several comorbidities. Our OMG cohort is an older population with several comorbidities. Final outcomes in those who received immunosuppression were similar to those who had not.
Assuntos
Autoanticorpos/metabolismo , Miastenia Gravis/epidemiologia , Miastenia Gravis/imunologia , Receptores Colinérgicos/imunologia , Adolescente , Adulto , Idoso , Idoso de 80 Anos ou mais , Inibidores da Colinesterase/uso terapêutico , Comorbidade , Feminino , Humanos , Terapia de Imunossupressão , Masculino , Pessoa de Meia-Idade , Miastenia Gravis/terapia , Brometo de Piridostigmina/uso terapêutico , Estudos Retrospectivos , Escócia , Adulto JovemRESUMO
INTRODUCTION: The MG-QOL15 is a validated, health-related quality of life (HRQOL) measure for myasthenia gravis (MG). Widespread use of the scale gave us the opportunity to further analyze its clinimetric properties. METHODS: We first performed Rasch analysis on >1,300 15-item Myasthenia Gravis Quality of Life scale (MG-QOL15) completed surveys. Results were discussed during a conference call with specialists and biostatisticians. We decided to revise 3 items and prospectively evaluate the revised scale (MG-QOL15r) using either 3, 4, or 5 responses. Rasch analysis was then performed on >1,300 MG-QOL15r scales. RESULTS: The MGQOL15r performed slightly better than the MG-QOL15. The 3-response option MG-QOL15r demonstrated better clinimetric properties than the 4- or 5-option scales. Relative distributions of item and person location estimates showed good coverage of disease severity. CONCLUSIONS: The MG-QOL15r is now the preferred HRQOL instrument for MG because of improved clinimetrics and ease of use. This revision does not negate previous studies or interpretations of results using the MG-QOL15. Muscle Nerve 54: 1015-1022, 2016.
Assuntos
Miastenia Gravis/diagnóstico , Miastenia Gravis/psicologia , Psicometria , Qualidade de Vida/psicologia , Humanos , Estudos RetrospectivosRESUMO
INTRODUCTION: We explored the modified Rankin scale (mRS) as a tool to quantitate disability in myasthenia gravis (MG). Our aim was to correlate patients' perception of their disability with that of the care provider and determine its relationship with other MG-related scores. METHODS: We evaluated 107 MG patients at 2 neurological centers. Patients were assessed over the telephone before and after clinic visits using the 15-item Myasthenia Gravis Quality-of-Life index (MG-QOL15) and mRS. At the clinic, patients were assessed using the MG-QOL15, MG Composite (MGC), and mRS. RESULTS: The MG-QOL15 correlated with the MGC, mRS, and assessors' scores of patients. Assessors' perception of disease burden was in line with that of the patients' scoring. MG-QOL15 scores obtained over the telephone were consistent with those obtained in the clinic. Scores were generally higher in patients receiving steroids at >5 mg/day and in those receiving or seeking benefits. CONCLUSION: The MG-QOL15 and mRS are useful for estimating disability in MG.
Assuntos
Avaliação da Deficiência , Miastenia Gravis/diagnóstico , Miastenia Gravis/fisiopatologia , Idoso , Idoso de 80 Anos ou mais , Pessoas com Deficiência , Feminino , Humanos , Masculino , Pessoa de Meia-Idade , Miastenia Gravis/psicologia , Psicometria , Qualidade de Vida , Autoavaliação (Psicologia) , Índice de Gravidade de Doença , Estatísticas não Paramétricas , Inquéritos e Questionários , TelefoneRESUMO
The Oculobulbar Facial Respiratory (OBFR) score is a tool that objectively measures bulbar function in myasthenia gravis (MG). In this study, we analyzed the relation between the OBFR and the MG Activities of Daily Living (MG-ADL) score, and also with the more recently described MG Composite and 15-item MG Quality-of-Life (MG-QOL15) scales. We recruited 42 patients from two centers and assessed them on two occasions, approximately 6 months apart, using the OBFR, MG Composite, MG-ADL, and MG-QOL15 scales. The 'modified' OBFR score was derived from the original OBFR score. The OBFR score correlated significantly with the MG Composite, MG-ADL, and MG-QOL15 scores for both assessments, and with the sum of the bulbar items for all three scores. It also correlated strongly with the individual bulbar-related items of all three scores. The 'modified' OBFR score also correlated significantly with all the aforementioned scores. This study confirmed construct validity of the OBFR and 'modified' OBFR scores.